Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction.
A Bozkurt, N E Basci, A Isimer, S O Kayaalp
Index: J. Pharm. Biomed. Anal. 11(8) , 745-9, (1993)
Full Text: HTML
Abstract
A simple, selective and sensitive method has been developed to determine debrisoquine and 4-hydroxydebrisoquine in human urine. Separation of the analytes was obtained using a mobile phase of 0.1 M sodium dihydrogen phosphate-acetonitrile (87:13, v/v) and a muBondapak C18 column. The column effluent was monitored with fluorescence detection at 210 nm (ex) and 290 nm (em). Rapid sample preparation was achieved by solid-phase extraction columns (Bond Elut CBA, 3 ml capacity) which provided excellent recovery values for both compounds. The cost per sample using this approach could be minimized by column regeneration and re-use. The within-day and the day-to-day reproducibilities were less than 7% for both components. The method was shown to be suitable for the study of the debrisoquine-sparteine type genetic polymorphism in man.
Related Compounds
Related Articles:
1999-08-01
[Biochem. Pharmacol. 58(3) , 439-45, (1999)]
Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
1998-03-01
[Br. J. Clin. Pharmacol. 45(3) , 315-7, (1998)]
2005-01-01
[Clin. Chem. Lab Med. 43(3) , 275-9, (2005)]
Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
1999-01-01
[Chirality 11(7) , 591-7, (1999)]
Debrisoquine hydroxylation in Parkinson's disease.
1992-08-01
[Acta Neurol. Scand 86(2) , 159-64, (1992)]